rfi press release final-11!04!2011

Upload: philomenebouchon

Post on 05-Apr-2018

214 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/2/2019 RFI Press Release Final-11!04!2011

    1/2

    Press Release

    EFPIA launches tendering process for its European MedicinesVerification System (EMVS)

    Brussels, 11 April 2012: The European Federation of Pharmaceutical Industries and Associations(EFPIA) is pleased to announce the official launch of the tendering process for key components ofits European Medicines Verification System (EMVS) as of 5 th April 2012.

    EFPIA plans to prove the efficiency and to demonstrate the viability of the EMVS through real-lifeimplementation ahead of the publication of the European Commissions Delegated Act on SafetyFeatures (expected by 2014). The stakeholder-governed solution proposed by EFPIA and its partners

    in the pharmaceutical supply chain is indeed likely to constitute the key solution for futureimplementation of the Falsified Medicines Directive.

    The EMVS will consist of the following key components:

    (1) One European Hub including the interfaces to manufacturer and parallel distributor systemsand to the national systems;

    (2) The template of a National Blueprint System (nBPS) including the interface to (a) theEuropean Hub and (b) the pharmacy and wholesaler systems.

    The tender process will comprise the following steps:

    1. Information for potential vendors and release of RFI to selected potential vendors on 5th

    April 2012;2. Information Workshop with public Question & Answers session Renaissance Hotel,

    Ballroom 2, Rue du Parnasse 12, 1050 Brussels on 19 th April 2012 (9.00h-13.00h);3. Evaluation of submitted responses to RFI by EFPIA and decision on vendor shortlist on 13 th

    June 2012;4. Release of request for proposal (RFP) to shortlisted vendors on 15 th June 2012 (deadline: 27 th

    July 2012);5. Evaluation of submitted responses to RFP and final decision by EFPIA on 4 th September 2012.

    Interested vendors (i.e. EDQM as a potential service provider) are invited to submit their RFIproposals by 25 th May 2012 (COB).

    Click here for further information on the tender process.

    ###

    http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834
  • 8/2/2019 RFI Press Release Final-11!04!2011

    2/2

    Fdration EuropennedAssociations et dIndustries Pharmaceutiques

    Leopold Plaza BuildingRue du Trne 108 Bote 1B-1050 Bruxelles

    T +32 2 626 25 55F +32 2 626 25 66www.efpia.eu

    Contacts Useful LinksAndreas M. WALTER, Coding & SerialisationProject Director E-mail: [email protected]

    HYPERLINK to practical informationwww.efpia.eu

    About EFPIA

    EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 31national associations and 35 leading pharmaceutical companies, EFPIA provides the voice of 2,000companies committed to researching, developing and bringing new medicines to improve health and qualityof life around the world.

    EFPIA members are committed to delivering innovative medicines to address unmet needs of patients and reducing the burden of chronic diseases for Eur opes ageing population. EFPIA believes in close cooperationwith its stakeholders to help create sustainable healthcare systems and to develop prompt responses to healththreats in Europe.

    The pharmaceutical sector directly employs some 640,000 people in Europe including 115,000 working in research and development in 2010. The industry also generates around three to four times more employment

    both upstream and downstream.

    Europes research -based pharmaceutical industry generates a substantial trade surplus, estimated at about 46,800 million in 2010, and has contributed significantly to reducing the European Unions trade deficit in high -tech products. 27,000 million were spent on research and development in Europe in 2010. Almost a quarter of the EUs high -tech exports are pharmaceutical products.

    mailto:[email protected]:[email protected]:[email protected]://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=12834mailto:[email protected]